News & Media / Newsroom
Innovation Pharmaceuticals announces License Agreement with Alfasigma S.p.A. for the development and commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis.
Alfasigma USA has acquired the brand ZELNORM (tegaserod), a treatment for IBS-C, from Sloan Pharma, with the aim to relaunch the brand in the United States.
The merger between the 3 Italian companies Alfa Wassermann, Sigma-Tau and Biofutura within Alfasigma SpA has been announced last August 1st.
Alfasigma announces the acquisition of Pamlab, a U.S. based company with a leading position in the manufacturing and distribution of medical foods, from Nestlé Health Science.
Over the last few days the operation foreseeing the transfer into the new holding company Alfasigma of the whole pharmaceutical activities and subsidiaries belonging to both Alfa Wassermann and Sigma-Tau, two of the most prominent Italian Pharmaceutical companies, has been fulfilled.
Alfa Wassermann and Sigma-Tau, two of the most important Italian pharmaceutical Groups, with strong international presence, signed an agreement to create a new company where each of them will contribute its pharmaceutical business.